Members of the
Introduction
Bcl-2 is well known to regulate the apoptosis of tumor cells. Originally, Bcl-2 was recognized as a molecule activated by chromosome translocation in follicular lymphoma. 1 Acquisition of drug resistance as a result of high level expression of Bcl-2 has been shown by in vitro experiments. 2, 3 In nonHodgkin's lymphoma, expression of Bcl-2 is reported to be an indicator of poor prognosis. 4 Expression of Bcl-2 in myeloma cells has been investigated by some groups. 5, 6 Sangfelt et al 7 reported that high level expression of Bcl-2 was correlated with resistance to IFN. Ong et al 8 showed that patients who survived for an extremely short time following diagnosis exhibited low levels of expression of Bcl-2 in myeloma cells. However, the significance of the expression of Bcl-2 in myeloma cells is still under debate. To investigate the significance of the expression of Bcl-2 in fresh myeloma cells, we utilized fresh samples and analyzed the correlation between clinical features and expression of Bcl-2.
Recently, many members of the Bcl-2 family of proteins, such as Bcl-X L , Bcl-Xs and Bax, have been identified. They are believed to regulate apoptosis by interacting with Bcl-2. 9 The expression of members of the Bcl-2 family of proteins in myeloma cells was studied to clarify the significance of these proteins in multiple myeloma.
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Materials and methods

Samples
Mononuclear cells were purified by Ficoll-Hypaque centrifugation from samples obtained from bone marrow, pleural effusions or peripheral blood. Cells were lysed in 0.5% NP-40/PBS containing protease inhibitors. After removing nuclei by centrifugation of the samples at 5000 r.p.m. for 5 min, lysates were frozen at −40°C until use. Normal bone marrow samples were obtained from two healthy donors. Three samples obtained under informed consent from two acute leukemia and one non-Hodgkin lymphoma patients at CR state were also analyzed.
Western blotting
Cell lysates (80 g) were applied to a 12% acrylamide gel, electrophoresed and transferred to nitrocellulose membrane. After subsequent blocking, membranes were reacted with anti-Bcl-2 (Cambridge Biochemicals, London, UK), anti-Bax or anti-Bcl-X L /s antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Then, membranes were incubated with peroxidase-conjugated secondary antibody and expression of each protein was visualized using a chemiluminescence detection kit (Amersham, Chelfont, UK). A myeloma cell line, KMS-12-PE, 10 was utilized as a positive control for the expression of Bcl-2 family proteins. Membranes were subsequently probed with either alkaline-phosphatase-conjugated anti-human kappa or lambda chain antibody (Sigma, St Louis, MO, USA) to confirm the quality of lysates. The substrate for alkaline phosphatase was purchased from Promega (Madison, WI, USA).
Results
The profiles of patients are shown in Table 1 . Representative results of Western blotting are shown in Figure 1 .
Bcl-2, Bcl-XL/s and Bax were not detected in two normal bone marrow samples and bone marrow samples from two acute leukemia and one non-Hodgkin lymphoma (data not shown). Statistical analysis showed that there was no correlation between the proportion of plasma cells and expression of Bcl-2 and Bcl-X L (R = 0.1496 and 0.2869, respectively analyzed by Kendall's correlation test). When comparing case 1 and 19, Bcl-2 was detected only in case 1 although a sample from case 19, contained more than 95% of plasma cells while a sample from case 1 contained 12.6% of plasma cells. A similar finding was found regarding expression of Bcl-X L , eg Bcl-X L was found in case 13 but not in case 9 despite a sample from case 13 containing 39% to tumor cells while a sample from case 9 had abundant plasma cells. These findings suggest that, at least in this study, the proportion of plasma cells may not alter the results of Western blot, although the possibility that heavy contamination of normal lymphocyte in samples 
pre, pre-treatment; post, post-treatment; PCL, plasma cell leukemia; G, lgG; A. lgA; BJP, Bence-Jones protein; K, kappa; L, lambda; BM, bone marrow; PC, plasmacytoma; PE, pleural effusion; PB, peripheral blood. which contain very few tumor cells would generate false negative results could not be ruled out.
Expression of Bcl-2 was found in 12 cases including all PCL cases. When PCL cases were excluded from analysis, six out of seven samples (6/7) from cases at stage I expressed Bcl-2 while three out of nine samples (3/9) from cases at stage III showed expression of Bcl-2 (P = 0.037) (Figure 2a) , suggesting Bcl-2 is preferentially expressed in tumor cells from patients at early clinical stages. There was no correlation of its expression and extramedullar invasion although all patients of PCL showed expression of Bcl-2 (cases 7,8 and 11) (P = 0.731) (Figure 2b ). There was no significant difference in the levels of expression of Bcl-2 either pre-treatment or post-treatment (P = 0.483) (Figure 2c) Bcl-X L was co-expressed with Bcl-2 in five samples (for cases 6-8, 11 and 12) and expressed alone in four samples (for cases 13, 14, 16 and 19) . No patient showed expression of Bcl-Xs. Bcl-X L tended to be expressed in patients with myeloma of advanced clinical stage since one out of seven patients at stage I showed expression of Bcl-X L while five out of nine were positive for Bcl-X L at stage III although there was no statistically significant difference (P = 0.103) (Figure 2d ). Eleven patients presented with extramedullar invasion of tumor cells including plasma cell leukemia (PCL) (cases 3, 4, 6-8, 11, 12, 14, 16, 19 and 20). Other than PCL cases (cases 7, 8 and 11), patients exhibited malignant pleuritis (cases 3, 6, 16, 19 and 20), plasmacytoma in the brain (case 4), plasmacytoma in the breast (case 12) and plasmacytoma in the chest wall (case 14). Bcl-X L was predominantly detected in patients with extramedullar lesions since only one out of nine patients showed expression of Bcl-X L without extramedullar invasion while eight out of 11 showed Bcl-X L expression with extramedullar invasion (P = 0.004, Student's t-test) (Figure 2e ). All patients with plasma cell leukemia (PCL) showed expression of Bcl-X L . There was no correlation between the level of expression of Bcl-X L and preceding chemotherapy (P = 0.605) (Figure 2f) .
Bax was found only in one case (case 19) who showed high serum LDH levels and malignant pleuritis caused by plasmacytoma on the chest wall.
The significance of Bcl-2 and Bcl-X L in prognosis was evaluated. Survival rate of cases with or without expression of Bcl-2 was almost similar throughout the period analyzed, eg the 5-year survival rate of patients not expressing Bcl-2 was 19.0% while that of patients expressing Bcl-2 was 20.8%, respectively. The survival rate of patients expressing Bcl-X L was lower than those not expressing it throughout the period of analysis, eg the 5-year survival rate of patients not expressing Bcl-X L was 43.8% while that of patients expressing Bcl-X L was 0% although there was no statistical significance. 
Discussion
To our knowledge, there have been three reports analyzing the expression of Bcl-2 in fresh myeloma cells. Brown et al 5 reported that 27% of myeloma patients expressed Bcl-2. Hamilton et al 6 showed that 80% of myeloma patients were Bcl-2 positive. Sangfelt et al 7 reported that high levels of expression of Bcl-2 were detected by immunohistochemistry in 43% of myeloma patients and this correlated with resistance to IFN. We found four patients with expression of Bcl-2 in eight untreated patients. Although the number of cases studied here is small, frequency of expression of Bcl-2 is compatible with previous reports. Ong et al 8 showed that patients who survived less than 1 year after diagnosis exhibited low levels of expression of Bcl-2. When PCL cases were excluded, our statistical analysis showed that Bcl-2 was significantly expressed in cases at stage I and its expression decreased at stage III. Our finding and a previous report by Ong may indicate that expression of Bcl-2 may decrease in tumor cells with high proliferation activity although our study demonstrated that Bcl-2 did not serve as a significant prognostic factor. One case (case 19), which had an aggressive clinical course, high serum LDH and extremely short survival (4 months), did not express Bcl-2, suggesting absence of Bcl-2 may be a feature of aggressive myeloma despite further cases should be analyzed. Bcl-2 was reported to be expressed in normal plasma cells. 6 We found that expression of Bcl-2 was expressed at an early stage. Taking these findings together, myeloma cells at early stage may still hold expression of Bcl-2 as a characteristic of normal plasma cells. At an advanced stage, expression of Bcl-2 may disappear as myeloma cells lose characteristics of normal plasma cells.
Statistical analysis revealed that Bcl-X L is preferentially expressed in tumor cells in extramedullar lesions, suggesting regulation of Bcl-X L is independent from that of Bcl-2. Bcl-X L may contribute to the drug resistance or apoptosis of myeloma cells in extramedullar lesions as reported for a murine plasma cell line. 11 Recently, it has been reported that Bcl-X L is overexpressed in a human myeloma cell line which is resistant to doxorubicin while expression of Bcl-2 was not altered. 12 Therefore, significance of Bcl-X L may be more important than that of Bcl-2 in myeloma cells. All patients with PCL showed expression of both Bcl-X L and Bcl-2.
There was no significant correlation between the level of expression of Bcl-2 or Bcl-X L and the occurrence of preceding chemotherapy. This finding was unexpected since we had speculated that exposure of myeloma cells to anti-cancer agents might induce expression of Bcl-2. Indeed, expression of Bcl-2 was reported to be induced by exposure of leukemia cells to steroids, 13 and in vitro experiments showed that a high level of expression of Bcl-2 is known to mediate drug resistance. 2 Although analysis of more cases and further in vitro studies are necessary to clarify the phenomenon, the initial levels of expression of Bcl-2 and Bcl-X L may be more important than the induction of these proteins by chemotherapy.
Bcl-2 and Bcl-X L expression was clearly detected in some cases while Bax expression was found in only one sample although we found that Bax was expressed in some myeloma cell lines (data not shown), indicating that expression of Bax may be induced during in vitro culture. Since Bax is considered to mediate the cytotoxicity of anti-cancer agents, 14, 15 the absence of Bax in most fresh myeloma cells may indicate the low sensitivity of tumor cells to anti-cancer agents as reported in breast cancer. 16 We found the expression of Bax without Bcl-2 expression in a patient of aggressive myeloma with high serum LDH level who showed resistance to chemotherapy (case 19). We established a cell line (KHM-11) from this patient 17 and found that the cell line also showed a high level of Bax expression and no expression of Bcl-2 (data not shown). A high Bax/Bcl-2 ratio may be a feature of high-grade myeloma although the mechanism of induction of Bax is unclear.
Taken together, expression of Bcl-2 family of proteins is regulated heterogeneously. The absence of Bax in most cases may cause the resistance of myeloma cells to chemotherapy. Bcl-2 may not be important as a factor mediating drug resistance in advanced clinical stage while Bcl-X L may play a role as an inhibitor of apoptosis at extramedullar lesions. Expression of Bax without Bcl-2 may be a feature of highgrade myeloma. Regulation of the expression of Bcl-2 family of proteins is an interesting area to analyze oncogenesis and the resistance to chemotherapy of myeloma cells.
